It is necessary to understand how rejection occurs, how the immune system distinguishes foreign tissues, and how to prevent rejection.
Key Takeaways
- Organ rejection occurs because the immune system is designed to recognise and eliminate anything that does not belong to the body, including a life-saving transplant.
- Rejection is classified into hyperacute, acute, and chronic forms, each driven by different immunological mechanisms and occurring over different timescales.
- Immunosuppressive therapy must be taken consistently for the life of the transplanted organ, and any interruption significantly raises rejection risk.
- Early detection through regular monitoring gives the best chance of reversing acute rejection before permanent graft damage occurs.
Why the Immune System Attacks Transplanted Organs
The immune system has developed the ability to distinguish what belongs to the body and what does not. The body has cell membrane proteins called human leukocyte antigens (HLA), which serve as identification for each cell. The immune system reacts by destroying foreign cells once it detects certain abnormal HLA patterns.
Therefore, any organ that has been transplanted, no matter how well it matches with the host's organ, has the donor's HLA profile. The only situation in which there is no HLA mismatch between donor and recipient is when the two people are identical twins. The greater the mismatch, the stronger the immune response is likely to be. The main components of the reaction are T-lymphocytes, especially CD4 helper T-cells and CD8 cytotoxic T-cells.
The Three Types of Rejection and Their Mechanisms
Hyperacute rejection happens soon after transplantation due to the body's existing antibodies that target the donor organ. The moment blood is re-established in the transplanted tissue, antibodies attack the walls of the graft's blood vessels, activating complement and leading to immediate thrombosis.
Acute rejection occurs some days after transplant. This rejection process is mediated by T-cells, which attack the transplanted organ. The generation of T-cells follows the reaction between the donor HLA and the recipient's T-cells.
Chronic rejection indicates a long process of progressive fibrosis and blood vessels impairment due to persistent immune stimulation.
How Rejection Is Detected
Signs and symptoms of acute rejection vary depending on the organ affected. In patients receiving kidney transplants, rejection manifests itself primarily in terms of rising creatinine, urine output, sensitivity or pain in the graft site, and sometimes fever. A biopsy of the transplanted kidney is the gold standard method for accurately diagnosing rejection and distinguishing between acute cellular and acute humoral rejection.
In addition, donor-specific antibody testing, blood complement levels, and monitoring of dd-cf DNA levels can be used to diagnose acute rejection at its early stages, before serious clinical manifestations arise.
Immunosuppression as the Foundation of Graft Survival
Know about Kidney Transplant and other solid organ transplant medicine. It is not easy to realise that immunosuppressive therapy is a constant requirement for the fate of the graft after transplant. The objective is to adequately inhibit the immune response to protect against rejection while avoiding the risk of infections or cancer.
The majority of transplant patients are treated with immunosuppressive drugs that work at different levels at the same time. A three-drug regimen including a calcineurin inhibitor, an antiproliferative drug, and a corticosteroid forms the international standard of immunosuppressive therapy for the majority of transplant programs.
Cyclosporine and Its Central Role
Cyclosporine is a calcineurin inhibitor that has represented a milestone in transplantation medicine since its introduction in the 1980s, and it remains one of the most widely used medications to facilitate organ transplantation. Cyclosporine exerts its action by interacting with cyclophilin – an intracellular protein. This process leads to the formation of a complex that inhibits calcineurin – the enzyme essential for the activation of the transcription factor NFAT and the production of interleukin-2.
Cyclosporine inhibits interleukin-2 production, thereby interrupting the chain of T-cell activation that would lead to rejection of the transplanted organ. Cyclophil ME 100 is a new form of cyclosporine in 100mg microemulsion that provides better oral bioavailability than the older oil-based formulations.
The medicine is taken twice a day at fixed times, and because cyclosporine is a narrow-therapeutic-index agent, blood levels need to be monitored frequently using trough measurements.
Managing Side Effects During Treatment
Cyclosporine-based therapy requires vigilant monitoring because of its potential to cause:
- Nephrotoxicity, particularly at higher blood levels, can paradoxically damage the transplanted kidney it is meant to protect.
- Hypertension, which affects a significant proportion of patients and requires antihypertensive management.
- Hyperlipidaemia increases cardiovascular risk over time.
- Gingival hyperplasia and hirsutism, which are cosmetically significant but medically manageable.
- Increased susceptibility to opportunistic infections and certain skin malignancies due to generalised immunosuppression.
Regular monitoring of blood counts, renal function, liver function, lipid profile, and blood pressure is a standard component of long-term follow-up for all patients on calcineurin inhibitor therapy.
Emotional and Mental Health During Recovery
The psychological aspect of living with a transplanted organ is often overlooked. Fear of organ rejection, the requirement for lifelong treatment and medications, worries about transplant-related infections, and concerns regarding donations are just some of the factors that can contribute to considerable psychological strain among transplant recipients.
Mental health professionals, peer support groups, and an open dialogue with the transplant medical team are all essential features of comprehensive post-transplant care.
Importance of Follow-Up Care
Post-transplant follow-up is not a formality. It is the mechanism through which rejection is caught early, drug levels are optimised, and the cumulative risks of long-term immunosuppression are managed.
Missing doses, missing blood tests, or delaying reporting of new symptoms all increase the risk of graft loss. For most transplant recipients, the relationship with their transplant centre is lifelong rather than time-limited.
What Is Worth Remembering
Organ rejection is not a failure of the transplant process. It is a predictable consequence of the immune system doing exactly what it evolved to do. What medicine offers is the ability to consistently interrupt that process, allowing the transplanted organ to function for years or decades.
That ability depends entirely on the immunosuppressive medication being taken as prescribed, the monitoring being maintained, and any changes in health or well-being being reported to the transplant team without delay.
Disclaimer: This article is for general informational purposes only and should not be considered medical advice. Always consult a qualified transplant specialist or healthcare professional for diagnosis, treatment, and guidance specific to your condition.